People | July 10, 2024
AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Subscribe To Our Newsletter & Stay Updated
